Bluejay Diagnostics, Inc.
BJDXBluejay Diagnostics, Inc. in brief
Bluejay Diagnostics, Inc. is a listed company in the Healthcare sector, based in Acton, Massachusetts, USA. Its market value was $5 M on 1 August 2026, which makes it the 26,867th largest listed company in the world and the 4,401st largest in the USA on this site. It employs about 6 people and Indranil Dey is its chief executive. Its shares trade under the symbol BJDX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform, which consists of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. We have completed the pre-clinical development of the Symphony analyzer. During 2026, we transferred the knowledge, technology and process underlying the production of the Symphony cartridges from the original developer and outside supplier, Toray Industries, to a contract manufacturing facility with FDA certification run by Sanyoseiko. We are also working with Sanyoseiko to modify the manufacturing process of the Symphony cartridges to address certain technical issues to bring Symphony to a level consistent with necessary performance and quality requirements for regulatory submission. To achieve our plan, we expect to need to raise at least $20 million of further capital by the end of the 2027 fiscal year, which we hope to do in various tranches.
From the company's annual report filed with the US SEC: read the report
Bluejay Diagnostics, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 November 2021; shares registered for exchange trading on 5 November 2021.
Events of Bluejay Diagnostics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,636 (Dec 2022) · #5,498 (Jul 2023) · #4,726 (Jan 2024) · #2,510 (Mar 2026) · #4,124 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.8×
- Free cash flow yield
- -124.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -114.5%
- Liabilities / assets
- 16.0%
- R&D / revenue
- 1660.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-7M | $-7M | — |
| Dec 2024 | — | — | $-7M | $-8M | — |
| Dec 2023 | — | — | $-10M | $-10M | — |
| Dec 2022 | $0M | — | $-9M | $-9M | -3720.0% |
| Dec 2021 | — | — | $-3M | $-3M | — |
| Dec 2020 | — | — | $-1M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-6M | $0M | $-6M | $-15.25 | — |
| Dec 2024 | $-8M | $0M | $-8M | $-456.75 | — |
| Dec 2023 | $-8M | $1M | $-9M | $-3631.48 | — |
| Dec 2022 | $-8M | $1M | $-9M | $-9.22 | — |
| Dec 2021 | $-4M | $0M | $-4M | $-0.41 | — |
| Dec 2020 | $-1M | — | — | $-0.37 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportBylaws amended · Shareholder vote · Other events
- Oct 13, 20268-KCurrent reportRegulation FD disclosure
- Oct 6, 20268-KCurrent reportRegulation FD disclosure
- Sep 8, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Aug 13, 20268-KCurrent reportRegulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jul 22, 20268-KCurrent reportRegulation FD disclosure
- Jun 9, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 8, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Jun 2, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
Official filings of Bluejay Diagnostics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-7 M
- Net income
- $-7 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $1 M
- Total equity
- $6 M
As of December-2025
Top 14 institutional investors in Bluejay Diagnostics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors LLC | 54,764 | New | 4.90% | $0 M | Nov 16, 2026 |
| 2 | Jane Street Group, LLC | 43,895 | New | 3.93% | $0 M | Nov 12, 2026 |
| 3 | Geode Capital Management, LLC | 39,602 | New | 3.55% | $0 M | Nov 6, 2026 |
| 4 | Susquehanna International Group, LLP | 27,684 | New | 2.48% | $0 M | Nov 16, 2026 |
| 5 | StoneX Group Inc. | 17,828 | New | 1.60% | $0 M | Nov 3, 2026 |
| 6 | Virtu Financial LLC | 12,027 | New | 1.08% | $0 M | Nov 17, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 10,225 | 0 (0.00%) | 0.92% | $0 M | Nov 13, 2026 |
| 8 | Tower Research Capital LLC (TRC) | 2,933 | +1,026 (+53.80%) | 0.26% | $0 M | Nov 16, 2026 |
| 9 | UBS Group AG | 596 | New | 0.05% | $0 M | Nov 10, 2026 |
| 10 | SBI Securities Co., Ltd. | 302 | New | 0.03% | $0 M | Oct 22, 2026 |
| 11 | L1 Global Manager Pty Ltd | 120 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 12 | Robinhood Markets, Inc. | 71 | — | 0.01% | $0 M | Nov 18, 2026 |
| 13 | Jpmorgan Chase & Co | 10 | New | 0.00% | $0 M | Nov 12, 2026 |
| 14 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Bluejay Diagnostics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 25,155 | $0 M | 2.3% | <0.01% | +183% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 183 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Bluejay Diagnostics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Indranil DeyPresident and CEO, Director | Grant or award | +28,000 | — | — | 40,522 | Form 4 |
| filed | HRT Financial LP10% owner | Sell | -34,938 | $1.400 | $49 K | 92,055 | Form 4 |
| filed | HRT Financial LP10% owner | Buy | +64,047 | $1.510 | $97 K | 126,993 | Form 4 |
| filed | Donald R. ChaseDirector | Buy | +12,500 | $2.000 | — | 12,525 | Form 4 |
| filed | Douglas Clark WurthDirector | Buy | +12,500 | $2.000 | — | 12,608 | Form 4 |
| filed | Indranil DeyPresident and CEO, Director | Buy | +12,500 | $2.000 | — | 12,522 | Form 4 |
| filed | Svetlana DeyDirector | Buy | +12,500 | $2.000 | $25 K | 12,501 | Form 4 |
| filed | Fred S. ZeidmanDirector | Buy | +12,500 | $2.000 | — | 12,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Bluejay Diagnostics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q3 2025 | Q3 2026 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $0.1M |
Trading halts
- 2026-11-03 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-01-29 00:50 UTC, code T3, resumed 14:00 UTC
- 2025-10-09 19:20 UTC, code LUDP, resumed 19:30 UTC
- 2025-10-09 19:15 UTC, code LUDP, resumed 19:20 UTC
- 2025-04-07 17:41 UTC, code LUDP, resumed 17:46 UTC
Fails to deliver
- : 2,116 shares at $0.59
- : 73,765 shares at $0.81
- : 70,033 shares at $0.81
- : 1,000 shares at $0.76
- : 5,605 shares at $0.91
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Bluejay Diagnostics, Inc. scorecard#
Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-15.25 vs -456.75Diluted EPS -15.25 in fiscal 2025 against -456.75 the year before (report's currency).
- ✗Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$1 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-117.0%-117.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.87 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Bluejay Diagnostics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | 249—100% | — | — | |
| Cost of revenue | — | — | — | 200—80.4% | — | — | |
| Gross profit | — | — | — | 49—19.6% | — | — | |
| Research and development | 3,046−12.2%— | 3,472−39.2%— | 5,715+37.6%— | 4,152+262%1667% | 1,148+118%— | 527—— | |
| Selling, general and administrative | — | — | 283−37.2%— | 451—181% | — | — | |
| Selling and marketing | — | 8.3−97.1%— | 283−37.2%— | 451+55.8%181% | 290+297%— | 73—— | |
| General and administrative | 3,907+5.9%— | 3,690−14.5%— | 4,313−9.4%— | 4,763+166%1913% | 1,792+201%— | 596—— | |
| Operating expenses | 6,953−3.0%— | 7,170−30.5%— | 10,311+10.1%— | 9,367+190%3761% | 3,230+170%— | 1,196—— | |
| Operating income | −6,953—— | −7,170—— | −10,311—— | −9,318—−3741% | −3,230—— | −1,196—— | |
| Interest and finance income | 98−33.1%— | 146−11.6%— | 165—— | — | — | — | |
| Interest expense and finance costs | 0.8−99.9%— | 823—— | — | — | 6.4−89.3%— | 59—— | |
| Net interest income | — | — | — | — | −367—— | −27—— | |
| Other non-operating income (expense) | 104—— | −548−253%— | 357+1616%— | 21—8.4% | −258−777%— | 38—— | |
| Net income including minority interests | — | — | — | — | −3,488—— | −1,158—— | |
| Net income attributable to shareholders | −6,848—— | −7,718—— | −9,954—— | −9,297—−3733% | −3,488—— | −1,158—— | |
| Earnings per share, basic | -15.25—— | -456.75r-114.19—— | -3,631.48r-9.08—— | -9.22r-0.46—— | -0.41—— | -0.37—— | |
| Earnings per share, diluted | -15.25—— | -456.75r-114.19—— | -3,631.48r-9.08—— | -9.22r-0.46—— | -0.41—— | -0.37—— | |
| Shares, weighted average (basic) | 0.4+879%— | 0.0r0.2+1573%— | 0.0r1.1−99.7%— | 1.0r20−88.2%— | 8.5—— | — | |
| Shares, weighted average (diluted) | 0.4+879%— | 0.0r0.2+1573%— | 0.0r1.1−99.7%— | 1.0r20−88.2%— | 8.5+171%— | 3.1—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 5,165+20.1%72.5% | 4,302+94.8%64.6% | 2,209−78.2%45.4% | 10,115−46.9%74.8% | 19,048+1988%90.6% | 912—60.1% | |
| Inventory | — | — | — | — | — | 85—5.6% | |
| Other current assets | 276−53.8%3.9% | 597−20.1%9.0% | 747−55.3%15.3% | 1,673+3.8%12.4% | 1,613+2541%7.7% | 61—4.0% | |
| Current assets | 5,464+11.5%76.7% | 4,899+52.1%73.6% | 3,221−72.7%66.2% | 11,788−42.9%87.2% | 20,660+1852%98.3% | 1,058—69.7% | |
| Property, plant and equipment | 1,534+1.4%21.6% | 1,513+17.7%22.7% | 1,286+4.4%26.4% | 1,232+265%9.1% | 337−26.5%1.6% | 459—30.3% | |
| Right-of-use (leased) assets | 113−46.0%1.6% | 210−37.1%3.2% | 333−28.4%6.8% | 466—3.4% | — | — | |
| Total assets | 7,119+6.9%100% | 6,657+36.7%100% | 4,869−64.0%100% | 13,521−35.7%100% | 21,019+1285%100% | 1,517—100% | |
| Accounts payable | 214+47.6%3.0% | 145−70.5%2.2% | 491−22.7%10.1% | 636+115%4.7% | 296−21.1%1.4% | 375—24.7% | |
| Current liabilities | 1,119+38.1%15.7% | 810−54.3%12.2% | 1,771+8.0%36.4% | 1,640+157%12.1% | 637—3.0% | — | |
| Lease liabilities (non-current) | 20−81.5%0.3% | 109−42.6%1.6% | 190−41.3%3.9% | 324—2.4% | — | — | |
| Total liabilities | 1,144+23.3%16.1% | 928−53.0%13.9% | 1,974−0.3%40.5% | 1,980+211%14.6% | 637−65.5%3.0% | 1,845—122% | |
| Retained earnings | −41,517—−583% | −34,669—−521% | −26,951—−554% | −16,997—−126% | −7,695—−36.6% | −4,206—−277% | |
| Shareholders' equity | 5,975+4.3%83.9% | 5,729+97.9%86.1% | 2,895−74.9%59.5% | 11,541−43.4%85.4% | 20,382—97.0% | −4,206—−277% | |
| Total liabilities and equity | 7,119+6.9%100% | 6,657+36.7%100% | 4,869−64.0%100% | 13,521−35.7%100% | 21,019+1285%100% | 1,517—100% | |
| Shares outstanding | 0.2r0.6+9.1%— | 0.1r0.6+4371%— | 0.0r1.2−99.7%— | 1.0r20−95.0%— | 20+539%— | 3.1—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | — | — | — | 157+7.5%62.9% | 146−7.2%— | 157—— | |
| Share-based compensation | 0.0−100.0%— | 20−89.4%— | 189−56.3%— | 433+533%174% | 68+1735%— | 3.7—— | |
| Cash from operating activities | −6,054—— | −7,821r−7,820—— | −8,314—— | −7,742—−3109% | −4,367—— | −509—— | |
| Capital expenditure | −174—— | −307—— | −704—— | −1,199—−482% | −24—— | — | |
| Cash from investing activities | −174—— | −307—— | −704—— | −1,199—−482% | −24—— | — | |
| Shares issued | 8,347−30.8%— | 12,069+659%— | 1,591—— | — | — | — | |
| Cash from financing activities | 7,090−30.6%— | 10,221r10,220+820%— | 1,112+13665%— | 8.1−100.0%3.2% | 22,526+1600%— | 1,325—— | |
| Change in cash | — | — | — | −8,933−149%−3587% | 18,135+2122%— | 816—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 3,952+31.1%— | 1,117+42.1%— | 1,438+61.6%— | 812+3.4%— | 586*+5.8%— | 786+42.4%— | 890−13.8%— | 785−41.2%— | 554*−56.9%— | 552—— | 1,032—— | 1,335—— | 1,286*—— | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | 6.4—— | 0.7*—— | |
| Selling and marketing | — | — | — | — | — | — | — | — | 0.8*—— | 0.8—— | 0.3—— | 6.4—— | — | |
| General and administrative | 3,859−2.6%— | 945+13.7%— | 911−16.8%— | 1,127+2.1%— | 876*−5.8%— | 831+2.7%— | 1,095+27.0%— | 1,104+1.6%— | 930*−15.4%— | 809—— | 862—— | 1,087—— | 1,100*—— | |
| Operating expenses | 7,811+12.0%— | 2,061+27.5%— | 2,349+18.3%— | 1,939+2.6%— | 1,462*−1.5%— | 1,617+18.8%— | 1,985+4.8%— | 1,889−22.2%— | 1,485*−37.8%— | 1,362—— | 1,895—— | 2,428—— | 2,387*—— | |
| Operating income | −7,811—— | −2,061—— | −2,349—— | −1,939—— | −1,462*—— | −1,617—— | −1,985—— | −1,889—— | −1,485*—— | −1,362—— | −1,895—— | −2,428—— | −2,387*—— | |
| Interest and finance income | 125+19.2%— | 50+161%— | 25−15.1%— | 19+5.9%— | 32*−18.4%— | 19−69.3%— | 29+89.9%— | 18−40.8%— | 39*—— | 62—— | 15—— | 30—— | — | |
| Interest expense and finance costs | — | — | — | — | 0.2*−74.3%— | 0.2−99.9%— | 0.2−100.0%— | — | 0.7*—— | 186—— | 626—— | — | — | |
| Other non-operating income (expense) | 126+0.8%— | 50+157%— | 25−12.7%— | 20−20.0%— | 32*−39.3%— | 19—— | 29—— | 24−75.4%— | 53*−37.3%— | −120—— | −580—— | 100—— | 84*—— | |
| Net income attributable to shareholders | −7,685—— | −2,012—— | −2,324—— | −1,919—— | −1,430*—— | −1,598—— | −1,957—— | −1,864—— | −1,432*—— | −1,482—— | −2,475—— | −2,328—— | −2,303*—— | |
| Earnings per share, basic | — | -1.72—— | -1.12—— | -1.95—— | — | -16.92r-1.01—— | -5.64r-1.41—— | -13.46r-3.37—— | — | -76.94r-0.16—— | -256.16r-5.12—— | -394.76r-0.99—— | — | |
| Earnings per share, diluted | — | -1.72—— | -1.12—— | -1.95—— | — | -16.92r-1.01—— | -5.64r-1.41—— | -13.46r-3.37—— | — | -76.94r-0.16—— | -256.16r-5.12—— | -394.76r-0.99—— | — | |
| Shares, weighted average (basic) | 1.2+1142%— | 1.2+1142%— | 2.1+500%— | 1.0+611%— | — | 0.1r1.6−50.6%— | 0.3r1.4+3489%— | 0.1r0.6+2248%— | — | 0.2r9.6—— | 0.0r0.5—— | 0.0r2.4—— | — | |
| Shares, weighted average (diluted) | 1.2+1142%— | 1.2+1142%— | 2.1+500%— | 1.0+611%— | — | 0.1r1.6−50.6%— | 0.3r1.4+3489%— | 0.1r0.6+2248%— | — | 0.2r9.6—— | 0.0r0.5—— | 0.0r2.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7,380—78.8% | 7,380+139%78.8% | 9,599+116%83.2% | 3,684+18.2%65.8% | 5,165+20.1%72.5% | 3,082−46.4%63.0% | 4,443−44.9%69.4% | 3,116+17.1%59.0% | 4,302+94.8%64.6% | 5,756—68.9% | 8,058—74.2% | 2,661—52.4% | 2,209—45.4% | |
| Other current assets | 146—1.6% | 146−13.8%1.6% | 203−33.6%1.8% | 270−40.8%4.8% | 276−53.8%3.9% | 169−79.1%3.5% | 305−68.2%4.8% | 456−42.2%8.6% | 597−20.1%9.0% | 812—9.7% | 960—8.8% | 789—15.5% | 747—15.3% | |
| Current assets | 7,539—80.5% | 7,539+125%80.5% | 9,815+107%85.1% | 3,967+11.1%70.9% | 5,464+11.5%76.7% | 3,353−48.9%68.6% | 4,749−47.3%74.2% | 3,572+3.5%67.7% | 4,899+52.1%73.6% | 6,568—78.6% | 9,018—83.0% | 3,450—68.0% | 3,221—66.2% | |
| Property, plant and equipment | 1,778—19.0% | 1,778+27.6%19.0% | 1,643+11.3%14.2% | 1,529+2.3%27.3% | 1,534+1.4%21.6% | 1,394−9.2%28.5% | 1,477−4.9%23.1% | 1,495+14.9%28.3% | 1,513+17.7%22.7% | 1,535—18.4% | 1,553—14.3% | 1,301—25.6% | 1,286—26.4% | |
| Right-of-use (leased) assets | 47—0.5% | 47−65.3%0.5% | 69−55.5%0.6% | 91−48.1%1.6% | 113−46.0%1.6% | 135−40.8%2.8% | 156−40.9%2.4% | 176−41.0%3.3% | 210−37.1%3.2% | 227—2.7% | 263—2.4% | 299—5.9% | 333—6.8% | |
| Total assets | 9,369—100% | 9,369+91.6%100% | 11,534+80.1%100% | 5,599+6.1%100% | 7,119+6.9%100% | 4,890−41.5%100% | 6,403−41.0%100% | 5,278+4.0%100% | 6,657+36.7%100% | 8,353—100% | 10,859—100% | 5,075—100% | 4,869—100% | |
| Accounts payable | 446—4.8% | 446+177%4.8% | 674+519%5.8% | 220−57.6%3.9% | 214+47.6%3.0% | 161−49.1%3.3% | 109−77.8%1.7% | 520+91.1%9.8% | 145−70.5%2.2% | 317—3.8% | 490—4.5% | 272—5.4% | 491—10.1% | |
| Current liabilities | 1,927—20.6% | 1,927+67.8%20.6% | 2,117+103%18.4% | 1,414+7.4%25.3% | 1,119+38.1%15.7% | 1,149+9.5%23.5% | 1,041−49.4%16.3% | 1,317−13.7%24.9% | 810−54.3%12.2% | 1,049—12.6% | 2,057—18.9% | 1,526—30.1% | 1,771—36.4% | |
| Lease liabilities (non-current) | — | — | — | — | 20−81.5%0.3% | 43−67.0%0.9% | 65−56.6%1.0% | 87−48.8%1.7% | 109−42.6%1.6% | 130—1.6% | 151—1.4% | 171—3.4% | 190—3.9% | |
| Total liabilities | 1,929—20.6% | 1,929+61.1%20.6% | 2,119+90.4%18.4% | 1,417+0.4%25.3% | 1,144+23.3%16.1% | 1,197+0.7%24.5% | 1,113−49.8%17.4% | 1,412−17.3%26.7% | 928−53.0%13.9% | 1,189—14.2% | 2,218—20.4% | 1,708—33.7% | 1,974—40.5% | |
| Retained earnings | −47,772—−510% | −47,772—−510% | −45,761—−397% | −43,437—−776% | −41,517—−583% | −40,087—−820% | −38,490—−601% | −36,533—−692% | −34,669—−521% | −33,237—−398% | −31,755—−292% | −29,279—−577% | −26,951—−554% | |
| Shareholders' equity | 7,441—79.4% | 7,441+101%79.4% | 9,415+78.0%81.6% | 4,181+8.1%74.7% | 5,975+4.3%83.9% | 3,693−48.5%75.5% | 5,290−38.8%82.6% | 3,866+14.8%73.3% | 5,729+97.9%86.1% | 7,164—85.8% | 8,641—79.6% | 3,367—66.3% | 2,895—59.5% | |
| Total liabilities and equity | 9,369—100% | 9,369+91.6%100% | 11,534+80.1%100% | 5,599+6.1%100% | 7,119+6.9%100% | 4,890−41.5%100% | 6,403−41.0%100% | 5,278+4.0%100% | 6,657+36.7%100% | 8,353—100% | 10,859—100% | 5,075—100% | 4,869—100% | |
| Shares outstanding | 1.1—— | 1.1−31.9%— | 2.0+32.8%— | 1.0+86.8%— | 0.2r0.6+9.1%— | 1.6−90.8%— | 1.5−42.2%— | 0.6−79.4%— | 0.1r0.6+4371%— | 18—— | 2.6—— | 2.7—— | 0.0r1.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | — | 56+30486%— | — | — | 0.1*—— | 0.2−96.2%— | −1.6−126%— | 1.3−89.0%— | — | 4.8—— | 6.0—— | 12—— | — | |
| Cash from operating activities | −6,546—— | −2,003*—— | −1,499*—— | −1,589—— | −1,455*—— | −1,360*—— | −2,054*—— | −1,185—— | −1,451r−1,739*—— | −2,155r−1,931*—— | −1,915r−1,854*—— | −2,300r−2,296—— | −2,777*—— | |
| Capital expenditure | — | −197*—— | −143*—— | −19—— | — | — | — | — | −1.1*—— | −0.2*—— | −270*—— | −35—— | −88*—— | |
| Cash from investing activities | — | −196*—— | −143*—— | −15—— | — | — | — | — | −1.1*—— | −0.2*—— | −270*—— | −35—— | −88*—— | |
| Shares issued | 13,125—— | 0*—— | 8,500*—— | 125—— | 4,500*—— | 0*—— | — | — | 0*—— | 0*—— | 8,569*—— | 3,500—— | 0*—— | |
| Shares bought back | — | −19*—— | — | — | — | 0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 11,372+237%— | −20*—— | 7,557*+123%— | 124—— | 3,711*—— | −1.0*—— | 3,381*−55.4%— | −1.0−100%— | −1.3r286*—— | −148r−371*—— | 7,582r7,521*—— | 2,788r2,784—— | −3.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Bluejay Diagnostics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 8 · Unregistered share sale 4 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 2
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Bluejay Diagnostics, Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2023, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2023
PLATINUM ADVISORS DC, LLC $30 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2023 | $30 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Bluejay Diagnostics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Bluejay Diagnostics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $175 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| CORPORATE CONTROLLERTreasurers and Controllers | 1 | $175 K |
Where: Acton, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $175 K | 1 |
| FY2025 | 1 | 1 | $120 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Bluejay Diagnostics Inc
How Bluejay Diagnostics, Inc. compares in Healthcare
- Market cap$5 M · higher than 4% of 2,013
- Price / book0.8× · lower than 86% of 1,245
- FCF yield-124.4% · higher than 6% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Bluejay Diagnostics, Inc.🇺🇸 | $5 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 2, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Bluejay Diagnostics, Inc.? Verify and update this profile — free
Show Bluejay Diagnostics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.